Antibody Fc Engineering: Towards Better Therapeutics
Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspec...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (118 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544224704498 |
---|---|
ctrlnum |
(CKB)4920000000094332 (oapen)https://directory.doabooks.org/handle/20.500.12854/40953 (EXLCZ)994920000000094332 |
collection |
bib_alma |
record_format |
marc |
spelling |
Rui Gong auth Antibody Fc Engineering: Towards Better Therapeutics Antibody Fc Engineering Frontiers Media SA 2018 1 electronic resource (118 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Open access Unrestricted online access star Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use. English effector function Fc receptor heterodimeric Fc Fc-fusion protein monomeric Fc Monoclonal antibody Fc engineering 2-88945-678-1 Tianlei Ying auth |
language |
English |
format |
eBook |
author |
Rui Gong |
spellingShingle |
Rui Gong Antibody Fc Engineering: Towards Better Therapeutics Frontiers Research Topics |
author_facet |
Rui Gong Tianlei Ying |
author_variant |
r g rg |
author2 |
Tianlei Ying |
author2_variant |
t y ty |
author_sort |
Rui Gong |
title |
Antibody Fc Engineering: Towards Better Therapeutics |
title_full |
Antibody Fc Engineering: Towards Better Therapeutics |
title_fullStr |
Antibody Fc Engineering: Towards Better Therapeutics |
title_full_unstemmed |
Antibody Fc Engineering: Towards Better Therapeutics |
title_auth |
Antibody Fc Engineering: Towards Better Therapeutics |
title_alt |
Antibody Fc Engineering |
title_new |
Antibody Fc Engineering: Towards Better Therapeutics |
title_sort |
antibody fc engineering: towards better therapeutics |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (118 p.) |
isbn |
2-88945-678-1 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT ruigong antibodyfcengineeringtowardsbettertherapeutics AT tianleiying antibodyfcengineeringtowardsbettertherapeutics AT ruigong antibodyfcengineering AT tianleiying antibodyfcengineering |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094332 (oapen)https://directory.doabooks.org/handle/20.500.12854/40953 (EXLCZ)994920000000094332 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Antibody Fc Engineering: Towards Better Therapeutics |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1789038446887567360 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02381nam-a2200385z--4500</leader><controlfield tag="001">993544224704498</controlfield><controlfield tag="005">20240124154537.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094332</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/40953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094332</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rui Gong</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antibody Fc Engineering: Towards Better Therapeutics</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Antibody Fc Engineering</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (118 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">effector function</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fc receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">heterodimeric Fc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fc-fusion protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">monomeric Fc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Monoclonal antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fc engineering</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-678-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tianlei Ying</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2024-01-25 02:20:43 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337599970004498&Force_direct=true</subfield><subfield code="Z">5337599970004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337599970004498</subfield></datafield></record></collection> |